KALA BIO, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. Co.'s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. Co.'s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. We show 30 historical shares outstanding datapoints in our KALA shares outstanding history coverage, used to compute KALA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KALA market cap history over the course of time is important for investors
interested in comparing KALA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KALA versus a peer is one thing; comparing
KALA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KALA can fluctuate over the course of history.
With this page we aim to empower investors researching KALA by allowing them to research the KALA market cap history. |
Free KALA Email Alerts:
Video: The Importance of Market Cap
